Source: International Congress 2017 – CAP: severity scores, risk groups and biomarkers
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
O. Okutan (Istanbul, Turkey). Proadrenomedullin (proADM) for clinical severity and prognosis in patients with pneumonia. 4112

Member's Comments

No comment yet.

Related content which might interest you: Procalcitonin and D-dimer to predict prognosis and clinical outcomes in severe community-acquired pneumonia (SCAP) patients Source: Annual Congress 2012 - Respiratory infections: a clinical point of view Year: 2012 Comparison of CPIS (clinical pulmonary infection score) and clinical criteria in the diagnosis of ventilator associated pneumonia in ICU complex patients Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007 Copeptin application in severe community-acquired pneumonia (SCAP) severity assessment and outcomes Source: Annual Congress 2012 - Respiratory infections: a clinical point of view Year: 2012 Biomarkers for the prognostic assessment and disease severity evaluation in community-acquired pneumonia (CAP) Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 Late-breaking abstract: Evaluation of CRP, PCT, clinical pulmonary infection score and pneumonia severity scores for the diagnosis and prognosis of nursing home acquired pneumonia Source: Annual Congress 2011 - Early diagnosis in primary care Year: 2011 The prognostic value of procalcitonin in patients with hypoxemic COVID 19 pneumonia. Source: Virtual Congress 2021 – COVID - 19 biomarkers Year: 2021 Diagnostic and prognostic utility of procalcitonin (PCT) measurements in patients with hospitalized community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers Year: 2009 The assessment of prognostic rules in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 149s Year: 2003 C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 545s Year: 2005 Biomarkers in severe community-acquired pneumonia (SCAP) prognosis, complications and outcomes Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Physicians should not use the pneumonia severity index (PSI) or CRB-65 in deciding the need for hospitalization in cancer patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 41s Year: 2007 Influence of statin therapy on clinical symptoms, severity and prognosis in patients with community acquired pneumonia Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia Year: 2008 Pro-adrenomedullin and pro-endothelin-1 for assessment and prognosis of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) Source: Eur Respir J 2007; 30: Suppl. 51, 39s Year: 2007 Admission lactate predicts poor prognosis independently of the CRB/CURB-65 scores in community-acquired pneumonia. Source: International Congress 2017 – Update on community acquired pneumonia Year: 2017 Assessment of prognostic scores for 30-day mortality prediction in hospitalised patients with health care associated pneumonia (HCAP) Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 preditive factors of severe outcome in patients with covid-19 pneumonia Source: Virtual Congress 2021 – COVID - 19 risk predictions Year: 2021 Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP) Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007 Procalcitonin and clinical pulmonary infection score as predictors of stroke associated pneumonia. Source: International Congress 2018 – Critically ill patients: prognostic factors and biomarkers Year: 2018 Steroids are not associated with an improvement in clinical outcomes in hospitalized patients with community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections Year: 2009 Pro-adrenomedullin as prognostic marker in patients with CAP Source: Annual Congress 2008 - Improved diagnosis and clinical decision-making by integrating information from new biomarkers Year: 2008